{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:24:30Z","timestamp":1794612270931,"version":"4.9.1"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2099"],"award-info":[{"award-number":["GRK2099"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010124","name":"Erich und Gertrud Roggenbuck-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ctrv.2021.102322","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T02:44:38Z","timestamp":1638326678000},"page":"102322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities"],"prefix":"10.1016","volume":"102","author":[{"given":"Alexander T.","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gorzelanny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2021.102322_b0005","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/ijms18081786","article-title":"A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy","volume":"18","author":"Kong","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060116-022926","article-title":"Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer","volume":"69","author":"Jenkins","year":"2018","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2017.01.006","article-title":"Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis","volume":"54","author":"Pasquali","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0025","doi-asserted-by":"crossref","first-page":"e001901","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2021.102322_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2021.102322_b0035","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102322_b0040","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Icht","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ctrv.2021.102322_b0045","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12102","article-title":"Managing thrombosis in cancer patients","volume":"2","author":"Wang","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2021.102322_b0055","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","article-title":"Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)","volume":"133","author":"Konigsbrugge","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102322_b0060","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0065","doi-asserted-by":"crossref","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0070","first-page":"423","article-title":"Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med (N Y)"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2021.102322_b0075","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","article-title":"The mechanisms of cancer-associated thrombosis","volume":"135","author":"Falanga","year":"2015","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102322_b0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1538-7836.2004.00721.x","article-title":"Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism","volume":"2","author":"Monreal","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2021.102322_b0090","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(07)70125-1","article-title":"Tissue factor and PAR signaling in tumor progression","volume":"120","author":"Ruf","year":"2007","journal-title":"Thromb Res"},{"issue":"04","key":"10.1016\/j.ctrv.2021.102322_b0095","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102322_b0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1055\/s-0037-1616053","article-title":"Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor","volume":"86","author":"Bromberg","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ctrv.2021.102322_b0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/ol.2011.291","article-title":"Protease-activated receptors in cancer: A systematic review","volume":"2","author":"Han","year":"2011","journal-title":"Oncol Lett"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2021.102322_b0110","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0049-3848(13)70024-0","article-title":"Mechanisms of thrombosis in cancer","volume":"131","author":"Falanga","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.ctrv.2021.102322_b0115","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","article-title":"The vessel wall and its interactions","volume":"111","author":"Wagner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0120","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","article-title":"von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans","volume":"125","author":"Bauer","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2021.102322_b0125","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2021.102322_b0130","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0135","first-page":"1","article-title":"Low-molecular-weight heparins and cancer: Focus on antitumoral effect","author":"Franchini","year":"2015","journal-title":"Ann Med"},{"issue":"42","key":"10.1016\/j.ctrv.2021.102322_b0140","doi-asserted-by":"crossref","first-page":"68527","DOI":"10.18632\/oncotarget.11832","article-title":"Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis","volume":"7","author":"Goertz","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0145","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ijc.30498","article-title":"D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress","volume":"140","author":"Desch","year":"2017","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.thromres.2013.01.015","article-title":"von Willebrand factor and cancer: a renewed interest","volume":"131","author":"Franchini","year":"2013","journal-title":"Thromb Res"},{"issue":"18","key":"10.1016\/j.ctrv.2021.102322_b0155","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1158\/0008-5472.CAN-16-0784","article-title":"Monocyte Induction of E-Selectin-Mediated Endothelial Activation Releases VE-Cadherin Junctions to Promote Tumor Cell Extravasation in the Metastasis Cascade","volume":"76","author":"H\u00e4uselmann","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.semcancer.2010.04.005","article-title":"Selectins promote tumor metastasis","volume":"20","author":"L\u00e4ubli","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"02","key":"10.1016\/j.ctrv.2021.102322_b0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0037-1613434","article-title":"Molecular mechanisms of leukocyte recruitment: organ-specific mechanisms of action","volume":"89","author":"Liu","year":"2003","journal-title":"Thromb Haemost"},{"issue":"04","key":"10.1016\/j.ctrv.2021.102322_b0170","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1160\/TH13-09-0800","article-title":"The various states of von Willebrand factor and their function in physiology and pathophysiology","volume":"111","author":"Huck","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ctrv.2021.102322_b0175","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2006-03-010322","article-title":"P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor","volume":"108","author":"Pendu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0180","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1182\/blood-2010-03-276311","article-title":"von Willebrand factor promotes leukocyte extravasation","volume":"116","author":"Petri","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0185","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012","journal-title":"J Exp Med"},{"issue":"7582","key":"10.1016\/j.ctrv.2021.102322_b0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2021.102322_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/701067","article-title":"Distinct Functions of Neutrophil in Cancer and Its Regulation","volume":"2015","author":"Granot","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ctrv.2021.102322_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040564","article-title":"Tumor-Associated Neutrophils in Cancer: Going Pro","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2021.102322_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8968943","article-title":"Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents","volume":"2019","author":"Minns","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ctrv.2021.102322_b0210","doi-asserted-by":"crossref","DOI":"10.1172\/JCI67484","article-title":"Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis","author":"Cools-Lartigue","year":"2013","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102322_b0215","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2021.102322_b0220","article-title":"Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis","author":"Sharma","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0225","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2016-09-741298","article-title":"Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102322_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090946","article-title":"Prognostic Role of Blood NETosis in the Progression of Head and Neck Cancer","volume":"8","author":"Decker","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2021.102322_b0235","article-title":"Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects","volume":"5","author":"Rayes","year":"2019","journal-title":"JCI insight"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102322_b0240","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-15-3051","article-title":"Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure","volume":"76","author":"Cedervall","year":"2016","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102322_b0245","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis","volume":"39","author":"Th\u00e5lin","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102322_b0255","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement\u2013their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Seminars Immunopathol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00281-017-0644-y","article-title":"Complement as a regulator of adaptive immunity","volume":"40","author":"Killick","year":"2018","journal-title":"Seminars Immunopathol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102322_b0270","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross Talk Pathways Between Coagulation and Inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102322_b0275","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-dependent roles of complement in cancer","volume":"19","author":"Roumenina","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2021.102322_b0280","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0285","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102322_b0290","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102322_b0295","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"issue":"02","key":"10.1016\/j.ctrv.2021.102322_b0300","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ctrv.2021.102322_b0305","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jneuroim.2014.11.016","article-title":"Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue","volume":"278","author":"Bouwens","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102322_b0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bjc.6602334","article-title":"Ascitic complement system in ovarian cancer","volume":"92","author":"Bj\u00f8rge","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2021.102322_b0315","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/jnci\/djt205","article-title":"Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer","volume":"105","author":"Ajona","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102322_b0320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2008.05.005","article-title":"Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer","volume":"69","author":"Ytting","year":"2008","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0325","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11037","article-title":"Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis","volume":"7","author":"Guglietta","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102322_b0330","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","article-title":"A Combined PD-1\/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis","volume":"7","author":"Ajona","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102322_b0335","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102322_b0340","doi-asserted-by":"crossref","first-page":"e001698","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2021.102322_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102322_b0350","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/eji.201847645","article-title":"Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient","volume":"48","author":"Horio","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0355","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","article-title":"Arterial thrombosis and anti-PD-1 blockade","volume":"91","author":"Boutros","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0360","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1159\/000492463","article-title":"Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases","volume":"11","author":"Tsukamoto","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102322_b0365","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1\/PD-L1 Monoclonal Antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0370","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102322_b0375","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/0008-5472.CAN-18-3206","article-title":"Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res"},{"issue":"39","key":"10.1016\/j.ctrv.2021.102322_b0380","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell-synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"issue":"6817","key":"10.1016\/j.ctrv.2021.102322_b0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/35051688","article-title":"Cardiovascular biology. Small cells, big issues","volume":"409","author":"Brass","year":"2001","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.ctrv.2021.102322_b0390","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102322_b0395","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.1601708","article-title":"Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis","volume":"198","author":"Zamora","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4860","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-beta","volume":"12","author":"Metelli","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2021.102322_b0405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060194","article-title":"TGF-beta in T Cell Biology: Implications for Cancer Immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2021.102322_b0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0415","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102322_b0420","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2021.102322_b0425","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102322_b0430","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1\/TGF-betaRII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102322_b0435","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00441-017-2727-4","article-title":"Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease","volume":"371","author":"Lisman","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ctrv.2021.102322_b0440","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2021.102322_b0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072249","article-title":"IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1","volume":"8","author":"de Kleijn","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102322_b0450","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2021.102322_b0455","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102322_b0460","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102322_b0470","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and Tolerability of c-MET Inhibitors in Cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2021.102322_b0475","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102322_b0480","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0485","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1373\/clinchem.2015.251314","article-title":"Complement C3 and High Risk of Venous Thromboembolism: 80517 Individuals from the Copenhagen General Population Study","volume":"62","author":"Norgaard","year":"2016","journal-title":"Clin Chem"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102322_b0490","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2021.102322_b0495","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1172\/JCI90962","article-title":"The role of the complement system in cancer","volume":"127","author":"Afshar-Kharghan","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2021.102322_b0500","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2021.102322_b0505","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102322_b0510","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","article-title":"Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum","volume":"87","author":"Shak","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2021.102322_b0515","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fimmu.2016.00373","article-title":"NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology","volume":"7","author":"Olsson","year":"2016","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102322_b0520","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/0008-5472.CAN-14-3299","article-title":"Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals","volume":"75","author":"Cedervall","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102322_b0525","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102322_b0530","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2021.102322_b0535","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins","volume":"125","author":"Borsig","year":"2010","journal-title":"Experimental evidence Thromb Res"},{"issue":"36","key":"10.1016\/j.ctrv.2021.102322_b0540","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102322_b0545","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102322_b0550","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:07Z","timestamp":1759656367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":109,"alternative-id":["S0305737221001705"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102322","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102322"}}